Sirolimus interferes with iron homeostasis in renal transplant recipients

被引:65
|
作者
Maiorano, Annamaria
Stallone, Giovanni
Schena, Antonio
Infante, Barbara
Pontrelli, Paola
Schena, Francesco Paolo
Grandaliano, Giuseppe
机构
[1] Univ Bari, Div Nephrol, Dept Emergency & Transplantat, I-70124 Bari, Italy
[2] Univ Foggia, Div Nephrol, Dept Biomed Sci, Foggia, Italy
关键词
sirolimus; anemia; renal transplantation; hepcidin;
D O I
10.1097/01.tp.0000235545.49391.1b
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Sirolimus is an immunosuppressive drug whose use is frequently associated with anemia. A pathogenic link between sirolimus-induced anemia and the appearance of an inflammatory state was recently suggested. Because inflammation-related anemia is characterized by a functional iron deficiency, we investigated whether sirolimus may influence iron homeostasis and serum levels of hepcidin, a key mediator of inflammation-related-anemia. Methods. To this purpose, 42 consecutive transplanted patients with biopsy-proven chronic allograft nephropathy were randomized (2:1 ratio) to receive either a 40% cyclosporine reduction (group A, 14 patients) or immediate cyclosporine withdrawal and sirolimus introduction (group B, 28 patients). Hemoglobin levels and iron status were evaluated 6 months before and after randomization. Results. The two groups had similar hemoglobin levels and iron status at baseline. We did not observe any significant change in hemoglobin and iron status in group A patients after randomization. On the contrary, we observed a significant reduction of hemoglobin without any change of red blood cell count after sirolimus introduction, with a significant reduction of mean corpuscular volume and mean corpuscular hemoglobin. Serum iron and transferrin saturation (TSAT) levels were markedly reduced after the switch, while ferritin serum concentrations remained stable. Although sirolimus-induced anemia was recently suggested to resemble inflammation-related anemia, hepcidin serum levels were similar in the two groups after randomization. None of group A and eight of group B patients presented a TSAT < 20 and were given iron supplementation after randomization, in all of them oral iron therapy did not influence either hemoglobin or serum iron levels. Conclusion. We demonstrated that sirolimus-induced anemia is independent of the drug antiproliferative effect and does not present the features of inflammation-related anemia. This event maybe due to the direct influence of sirolimus on iron homeostasis.
引用
收藏
页码:908 / 912
页数:5
相关论文
共 50 条
  • [31] Randomized Controlled Trial of Sirolimus Conversion in Cardiac Transplant Recipients With Renal Insufficiency
    Zuckermann, A.
    Keogh, Anne
    Crespo-Leiro, M. G.
    Mancini, D.
    Gonzalez Vilchez, F.
    Almenar, L.
    Brozena, S.
    Eisen, H.
    Tai, S. See
    Kushwaha, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (09) : 2487 - 2497
  • [32] Iron homeostasis in heart transplant recipients randomized to ferric derisomaltose or placebo
    Englund, Kristine V. Brautaset
    Ostby, Charlotte M.
    Broch, Kaspar
    Ueland, Thor
    Aukrust, Pal
    Gude, Einar
    Andreassen, Arne K.
    Gullestad, Lars
    CLINICAL TRANSPLANTATION, 2022, 36 (07)
  • [33] Sirolimus and angiotensin-converting enzyme inhibitors together induce tongue oedema in renal transplant recipients
    Stallone, G
    Infante, B
    Di Paolo, S
    Schena, A
    Grandaliano, G
    Gesualdo, L
    Schena, FP
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (11) : 2906 - 2908
  • [34] Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients
    Sundberg, AK
    Rohr, MS
    Hartmann, EL
    Adams, PL
    Stratta, RJ
    CLINICAL TRANSPLANTATION, 2004, 18 : 61 - 66
  • [35] Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients
    Wu, FLL
    Tsai, MK
    Chen, RRL
    Sun, SW
    Huang, JD
    Hu, RH
    Chen, KH
    Lee, PH
    PHARMACOTHERAPY, 2005, 25 (05): : 646 - 653
  • [36] Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients
    Knight, Richard J.
    Villa, Martin
    Laskey, Robert
    Benavides, Carlos
    Schoenberg, Linda
    Welsh, Maria
    Kerman, Ronald H.
    Podder, Hemangshu
    Van Buren, Charles T.
    Katz, Stephen M.
    Kahan, Barry D.
    CLINICAL TRANSPLANTATION, 2007, 21 (04) : 460 - 465
  • [37] Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus
    Casas-Melley, AT
    Falkenstein, KP
    Flynn, LM
    Ziegler, VL
    Dunn, SP
    PEDIATRIC TRANSPLANTATION, 2004, 8 (04) : 362 - 366
  • [38] Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients
    Kahan, BD
    Yakupoglu, YK
    Schoenberg, L
    Knight, RJ
    Katz, SM
    Lai, D
    Van Buren, CT
    TRANSPLANTATION, 2005, 80 (06) : 749 - 758
  • [39] Interstitial Fibrosis Quantification in Renal Transplant Recipients Randomized to Continue Cyclosporine or Convert to Sirolimus
    Servais, A.
    Meas-Yedid, V.
    Toupance, O.
    Lebranchu, Y.
    Thierry, A.
    Moulin, B.
    Etienne, I.
    Presne, C.
    Hurault, de Ligny B.
    Le Pogamp, P.
    Le Meur, Y.
    Glotz, D.
    Hayem, C.
    Marin, J. C. Olivo
    Thervet, E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (11) : 2552 - 2560
  • [40] CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients
    Li, Yi
    Yan, Lin
    Shi, Yunying
    Bai, Yangjuan
    Tang, Jiangtao
    Wang, Lanlan
    SPRINGERPLUS, 2015, 4